Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...